Digital Health Impact 2020

September 30, 2020 9:30 AM - 2:00 PM

Online Conference, Link will be sent in advance of the event.

Add to Calendar 9/30/2020 9:30:00 AM 9/30/2020 2:00:00 PM Digital Health Impact 2020

The convergence between digital health and the life sciences is creating new opportunities to transform patient care as well as drug discovery and development. From wearables to machine learning, digital technologies are easing data collection from patients, increasing medical adherence, supplementing clinical trials, and offering new insights into real-world applications of therapies. Embedding digital health tools into the life sciences will also allow new therapies to better work within the growing value-based healthcare system that relies on data and measurable outcomes.

Join MassBio for our annual Digital Health Impact 2020 event as we examine the current state of digital health as it relates to the life sciences, the challenges facing its growth, and opportunities for collaboration. Through keynotes, panel discussions, and case studies, we’ll explore new strategies for therapeutics and digital health innovators to converge and ultimately deliver better outcomes for patients.

Please contact Laura Rudberg for sponsorship opportunities.

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

 Online Conference, Link will be sent in advance of the event.
Head, R&D Digital Strategy Group, Data Sciences Institute, Takeda
Shoibal is the Head of the Digital Strategy Group within the Data Sciences Institute at Takeda. In support of Takeda's commitment to digital and data he is responsible for working with colleagues across the enterprise to develop patient-centric digital strategies for the development of novel endpoints and make studies more resilient through decentralized approaches. Prior to this Shoibal was Vice President of PPD Digital where he was responsible for setting the strategy and working with external platform partners and device manufacturers to devise compliant, globally scalable approaches to conduct decentralized trials and to oversee the integration of the technologies into conventional clinical research and data management processes. Prior to that, he spent 13 years at Biogen in a range of roles in translational informatics, data sciences and as part of an innovation hub that launched MS PATHS, a learning healthcare system that utilises technology to capture high quality data as standard of care for over 10,000 MS patients globally supporting RWE and value-based medicine initiatives.

Brought to you by